← All trials
NCT05946642
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2023
- Primary completion
- May 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jul 14, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 13000
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Malaria ConsortiumLead sponsor
- Malaria ConsortiumOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.